IF 6 2区 医学 Q1 CHEMISTRY, MEDICINAL European Journal of Medicinal Chemistry Pub Date : 2025-02-18 DOI:10.1016/j.ejmech.2025.117402
Gianluigi Lauro , Michela Aliberti , Mauro De Nisco , Silvana Pedatella , Giacomo Pepe , Manuela Giovanna Basilicata , Maria Giovanna Chini , Katrin Fischer , Robert K. Hofstetter , Oliver Werz , Maria Grazia Ferraro , Marialuisa Piccolo , Carlo Irace , Anella Saviano , Pietro Campiglia , Alessia Bertamino , Carmine Ostacolo , Tania Ciaglia , Michele Manfra , Giuseppe Bifulco
{"title":"Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition","authors":"Gianluigi Lauro ,&nbsp;Michela Aliberti ,&nbsp;Mauro De Nisco ,&nbsp;Silvana Pedatella ,&nbsp;Giacomo Pepe ,&nbsp;Manuela Giovanna Basilicata ,&nbsp;Maria Giovanna Chini ,&nbsp;Katrin Fischer ,&nbsp;Robert K. Hofstetter ,&nbsp;Oliver Werz ,&nbsp;Maria Grazia Ferraro ,&nbsp;Marialuisa Piccolo ,&nbsp;Carlo Irace ,&nbsp;Anella Saviano ,&nbsp;Pietro Campiglia ,&nbsp;Alessia Bertamino ,&nbsp;Carmine Ostacolo ,&nbsp;Tania Ciaglia ,&nbsp;Michele Manfra ,&nbsp;Giuseppe Bifulco","doi":"10.1016/j.ejmech.2025.117402","DOIUrl":null,"url":null,"abstract":"<div><div>We report the identification of a new set of compounds based on the furazanopyrazine core interfering with eicosanoid biosynthesis and acting as potentially effective anti-inflammatory and anticancer agents. Based on our previous promising results on a set of furazanopyrazine-based compounds against the microsomal prostaglandin E<sub>2</sub> synthase-1 (mPGES-1) enzyme, we here identified derivatives with improved pharmacokinetic properties by replacing the ester moiety with a more stable ether group.</div><div>A focused virtual library of 1 × 10<sup>4</sup> molecules was built and screened against mPGES-1 through molecular docking experiments, leading to the selection of 10 candidates for synthesis and biological evaluation. Several molecules were found to inhibit mPGES-1 and, among them, two items featured IC<sub>50</sub> values in the low micromolar range. Additional computational studies on the collection of synthesized compounds demonstrated that compound <strong>3b</strong>, previously emerged as an mPGES-1 inhibitor, interfered with soluble epoxide hydrolase (sEH) activity, thus emerging as a valuable dual mPGES-1/sEH inhibitor. The pharmacokinetic features of the most potent compounds were accurately estimated. Unfortunately, poor outcomes were obtained for <strong>3b</strong>; on the other hand, compound <strong>7e</strong> exhibited promising mPGES-1 inhibition and excellent pharmacokinetic profile, demonstrating that the novel furazanopyrazine-based items with ether moiety possess improved pharmacokinetic properties compared to the ester-based compounds reported in our previous study. Additionally, the anticancer properties of <strong>7e</strong> and <strong>7d</strong>, the latter emerged as the most active mPGES-1 inhibitor, were evaluated and both compounds showed promising activities against HCT-116 human colorectal cancer (CRC) cells.</div><div>These findings highlight the furazanopyrazine core as a promising scaffold for disclosing new anti-inflammatory drugs with the ability to inhibit targets belonging to arachidonic acid cascade.</div></div>","PeriodicalId":314,"journal":{"name":"European Journal of Medicinal Chemistry","volume":"289 ","pages":"Article 117402"},"PeriodicalIF":6.0000,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0223523425001679","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

我们报告了一组基于呋喃并吡嗪核心的新化合物的鉴定结果,这些化合物可干扰二十碳烷类化合物的生物合成,并可作为潜在有效的抗炎药和抗癌药。基于我们之前针对微粒体前列腺素 E2 合酶-1(mPGES-1)的一组呋喃并吡嗪类化合物所取得的令人鼓舞的成果,我们在这里通过用更稳定的醚基取代酯基,鉴定出具有更好药代动力学特性的衍生物。研究发现,一些分子对 mPGES-1 具有抑制作用,其 IC50 值在低微摩尔范围内。对合成的化合物集进行的其他计算研究表明,之前作为 mPGES-1 抑制剂出现的化合物 3b 干扰了可溶性环氧化物水解酶(sEH)的活性,因此成为一种有价值的 mPGES-1/sEH 双重抑制剂。我们准确地估算了药效最强的化合物的药代动力学特征。遗憾的是,3b 的药代动力学结果不佳;而化合物 7e 则表现出了良好的 mPGES-1 抑制作用和药代动力学特征,这表明与我们之前研究中报道的酯基化合物相比,新型呋喃并吡嗪类醚官能团化合物具有更好的药代动力学特性。此外,我们还评估了 7e 和 7d(后者是活性最强的 mPGES-1 抑制剂)的抗癌特性,这两种化合物对 HCT-116 人结肠直肠癌(CRC)细胞都显示出良好的活性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Furazanopyrazine-based novel promising anticancer agents interfering with the eicosanoid biosynthesis pathways by dual mPGES-1 and sEH inhibition
We report the identification of a new set of compounds based on the furazanopyrazine core interfering with eicosanoid biosynthesis and acting as potentially effective anti-inflammatory and anticancer agents. Based on our previous promising results on a set of furazanopyrazine-based compounds against the microsomal prostaglandin E2 synthase-1 (mPGES-1) enzyme, we here identified derivatives with improved pharmacokinetic properties by replacing the ester moiety with a more stable ether group.
A focused virtual library of 1 × 104 molecules was built and screened against mPGES-1 through molecular docking experiments, leading to the selection of 10 candidates for synthesis and biological evaluation. Several molecules were found to inhibit mPGES-1 and, among them, two items featured IC50 values in the low micromolar range. Additional computational studies on the collection of synthesized compounds demonstrated that compound 3b, previously emerged as an mPGES-1 inhibitor, interfered with soluble epoxide hydrolase (sEH) activity, thus emerging as a valuable dual mPGES-1/sEH inhibitor. The pharmacokinetic features of the most potent compounds were accurately estimated. Unfortunately, poor outcomes were obtained for 3b; on the other hand, compound 7e exhibited promising mPGES-1 inhibition and excellent pharmacokinetic profile, demonstrating that the novel furazanopyrazine-based items with ether moiety possess improved pharmacokinetic properties compared to the ester-based compounds reported in our previous study. Additionally, the anticancer properties of 7e and 7d, the latter emerged as the most active mPGES-1 inhibitor, were evaluated and both compounds showed promising activities against HCT-116 human colorectal cancer (CRC) cells.
These findings highlight the furazanopyrazine core as a promising scaffold for disclosing new anti-inflammatory drugs with the ability to inhibit targets belonging to arachidonic acid cascade.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
11.70
自引率
9.00%
发文量
863
审稿时长
29 days
期刊介绍: The European Journal of Medicinal Chemistry is a global journal that publishes studies on all aspects of medicinal chemistry. It provides a medium for publication of original papers and also welcomes critical review papers. A typical paper would report on the organic synthesis, characterization and pharmacological evaluation of compounds. Other topics of interest are drug design, QSAR, molecular modeling, drug-receptor interactions, molecular aspects of drug metabolism, prodrug synthesis and drug targeting. The journal expects manuscripts to present the rational for a study, provide insight into the design of compounds or understanding of mechanism, or clarify the targets.
期刊最新文献
A systematic review on the anti-microbial activities and structure-activity relationship (SAR) of quinoxaline derivatives Synthesis and bioactivity of cyclic peptide GG-8-6 analogues as anti-hepatocellular carcinoma agents Epigenetic Targets and Their Inhibitors in the Treatment of Idiopathic Pulmonary Fibrosis Combination therapy and dual-target inhibitors based on cyclin-dependent kinases (CDKs): Emerging strategies for cancer therapy Corrigendum to “Ultra-short lipopeptides containing d-amino acid exhibiting excellent stability and antibacterial activity against Gram-positive bacteria” [Europ. J. Med. Chem. 287 (2025) 117341]
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1